Prostate Cell News Volume 16.19 | Oct 10 2025

    0
    35







    2025-10-10 | PCN 16.19


    Vol. 16.19 – 10 October, 2025
    TOP STORY

    Niraparib and Abiraterone Acetate Plus Prednisone for HRR-Deficient Metastatic Castration-Sensitive Prostate Cancer: A Randomized Phase III Trial

    Investigators hypothesized that PARP inhibition within six months of starting androgen deprivation therapy for metastatic castration-sensitive prostate cancer could be effective and improve radiographic progression-free survival when added to standard-of-care treatments.
    [Nature Medicine]

    Full Article
    Tips to help you decide whether to pursue a postdoctoral position.
    PUBLICATIONSListed by the impact factor of the journal

    Targeting Histone H2B Acetylated Enhanceosomes via P300/CBP Degradation in Prostate Cancer

    Researchers identified p300/CBP-mediated multisite histone H2B N-terminal acetylation as a defining feature of oncogenic enhanceosomes in androgen receptor-positive prostate cancer.
    [Nature Genetics]

    Full Article

    Recurrent Immunogenic Neoantigens and Their Cognate T Cell Receptors in Treatment-Resistant Metastatic Prostate Cancer

    Scientists demonstrated that androgen receptor (AR) H875Y specific T cell receptors are highly specific and kill prostate cancer cells presenting AR neo-peptides in vitro and in vivo.
    [Cancer Discovery]

    Abstract

    Elucidating Molecularly Stratified Single Agent, and Combination, Therapeutic Strategies Targeting MCL1 for Lethal Prostate Cancer

    Researchers characterize MCL1 in multiple metastatic CRPC biopsy cohorts and patient-derived models, assessing responses to MCL1 inhibition.
    [Nature Communications]

    Full Article

    Combined SNPs Sequencing and Allele Specific Proteomics Capture Reveal Functional Causality Underpinning the 2p25 Prostate Cancer Susceptibility Locus

    Clinical findings revealed a synergistic effect between rs4519489 genotype and NOL10 expression on prostate cancer prognosis and severity.
    [Nature Communications]

    Full Article

    Preclinical Activity of the DLL3-Targeted T Cell Engager MK-6070 in Neuroendocrine Prostate Cancer

    Investigators reported the preclinical activity of MK-6070 in prostate cancer models, showing high specificity and anti-tumor activity in DLL3-expressing neuroendocrine prostate cancer models both in vitro and in vivo, with T cell activation and tumor infiltration of T cells after treatment.
    [Molecular Cancer Therapeutics]

    Abstract
    REVIEWS

    A Review of Exercise-Induced Epigenetic Modifications in Prostate Tissue: Implications for Gene Expression and Tumor Progression in Prostate Cancer

    There is growing evidence that physical exercise is associated with epigenetic alterations in prostate tissue, although its consequences on the prostate are yet unknown. Scientists summarize research on the molecular processes and therapeutic applications of exercise in prostate tissue.
    [Cancer Cell International]

    Full Article
    INDUSTRY AND POLICY NEWS

    New Alliance Trial Aims to Improve Outcomes in Metastatic Prostate Cancer

    The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial, a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.
    [The Alliance for Clinical Trials in Oncology (EurekAlert)]

    Press Release

    Vir
    Biotechnology Announces First Patient Dosed in Part 3 of Phase I Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

    Vir Biotechnology, Inc. announced that the first patient has been dosed in Part 3 of the Company’s Phase I clinical trial evaluating VIR-5500 in combination with androgen receptor pathway inhibitors.
    [Vir Biotechnology, Inc.]

    Press Release
    FEATURED EVENT

    Frontiers in Cancer Science 2025

    November 5-7, 2025
    Singapore

    > See All Events

    JOB OPPORTUNITIES

    Laboratory Research Assistant – Urology

    Indiana University – Indianapolis, Indiana, United States

    Research Assistant – Molecular Pharmacology and Experimental Therapeutics

    Mayo Clinic – Rochester, Minnesota, United States

    Clinical Research Fellow – Prostate Cancer

    University College London – London, England, United Kingdom

    Postdoctoral Associate – Genitourinary Cancers

    University of Miami Desai Sethi Urology Institute – Miami, Florida, United States

    Assistant/Associate/Senior Scientist – Cancer Research

    Henry Ford Health + Michigan State – Detroit, Michigan, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2